A regularly updated video series answering a selection of frequently asked investor questions
January 27, 2020
Dry AMD Competitive Landscape Overview & OpRegen Positioning
January 9, 2020
VAC2 Program & Research Partnership with CRUK
December 31, 2019
Review of cost efficient business model & plans for 2020
December 17, 2019
Review of recent results from OpRegen Phase I/IIa study
Key opinion leaders discuss topics related to Lineage’s clinical programs
OpRegen® – A Discussion of Retinal Tissue Regeneration in Dry-AMD with Geographic Atrophy
June 8, 2020
Therapeutic Expert Call to Discuss OpRegen Phase 1/2a Clinical Study Results
Christopher D. Riemann, M.D. Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute
May 11, 2020
OpRegen® Phase 1/2a Clinical Study Results
2020 ARVO Meeting
Christopher D. Riemann, M.D., Cincinnati Eye Institute (CEI)
Why is dry age-related macular degeneration (dry AMD) research so important?
Allen C. Ho, M.D., Wills Eye Hospital Director of Retina Research
Why is spinal cord research so important?
Dr. John Steeves, Emeritus Principal Investigator @ICORD and Professor @UBC
Presentations from specific events, conferences, or showcases
2020 Solebury Trout Virtual Investor Conference
NobleCon16 Investor Conference Webcast
H.C.Wainwright & Co. Annual Global Investment Conference
Data on OpRegen for Geographic Atrophy
Retina specialists discuss encouraging early results.
July 1, 2020
Lumiseek: The Cancer Impact Network Podcast
Dr. Bindu, CEO Lumiseek, interviews our CEO Brian Culley – Apr. 3rd, 2020
Solebury Trout Talks
Lineage Cell CEO encouraged about its dry AMD data
CEO Brian Culley chats with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco
A selection of patient focused media related to our cell therapy programs
5 years through the eyes of a mum.
A powerful dramatization of living with the progression of vision loss related to AMD. Source: www.macularsociety.org
Spinal Cord Injury and Lineage’s OPC1 Cell Therapy
An instructive whiteboard video explaining how spinal cord injury disrupts normal bodily function as well as OPC1 administration and mechanism of action.
OPC1 Program – Patient Spotlight
Highlighting the progress made by Kris Boesen and Lucas Lindner, both of whom received Lineage’s OPC1 cell therapy following traumatic spinal cord injury (SCI).
Lucas Lindner was paralyzed from the neck down following a car accident. The next year, he threw out the first pitch at a Major League Baseball game.
Watch the video above to learn more about Lucas’ journey.